NCT04991896View on ClinicalTrials.gov

Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS)

CompletedOBSERVATIONAL
Enrollment

81

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Atrial FibrillationArrhythmias, Cardiac
Interventions
DRUG

Flecainide Injectable Product

Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history.

Trial Locations (1)

82100

Skylitseio General Hospital, Chios

All Listed Sponsors
collaborator

Skylitseio General Hospital

UNKNOWN

lead

AHEPA University Hospital

OTHER

NCT04991896 - Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS) | Biotech Hunter | Biotech Hunter